Oncology Drug Reference Sheet: Margetuximab-Cmkb
Kristine B. LeFebvre, DNP, RN, NPD-BC, AOCN®
Voice
Description
Margetuximab-cmkb (Margenza®) received U.S. Food and Drug Administration approval in December 2020 for previously treated adults with metastatic HER2-positive breast cancer after clinical trials demonstrated increased progression-free and overall survival.